Ribavirin in the treatment of severe acute respiratory syndrome (SARS)

Netherlands Journal of Medicine

Volumn 61, Issue 7, 2003, Pages 238-241

  van Vonderen, M G A ^a   Bos, J C ^a   Prins, J M ^a   Wertheim van Dillen, P ^a   Speelman, P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BUDESONIDE; CORTICOSTEROID; HYDROCORTISONE; LAMIVUDINE; METHYLPREDNISOLONE; PREDNISOLONE; RIBAVIRIN; ANTIVIRUS AGENT;

ANEMIA; BONE MARROW SUPPRESSION; BRADYCARDIA; BRONCHIOLITIS; BRONCHOSPASM; CONJUNCTIVITIS; COUGHING; DEPRESSION; DRUG COST; DRUG ELIMINATION; DRUG ERUPTION; DRUG MECHANISM; HEART ARRHYTHMIA; HEMATOLOGIC DISEASE; HEMOGLOBINOPATHY; HEMOLYSIS; HEMOSIDEROSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMMONEMIA; HYPERBILIRUBINEMIA; HYPERURICEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; LASSA FEVER; LIVER TOXICITY; LUNG TOXICITY; NAUSEA; NONHUMAN; PANCREATITIS; PATHOGENESIS; PNEUMONIA; PRURITUS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RIGOR; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TERATOGENICITY; ANIMAL; CLINICAL TRIAL; DISEASE MODEL; IN VITRO STUDY; MOUSE;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; MICE; RIBAVIRIN; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 0242272430     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Koren G, King S, Knowles, Philips E. Ribavirin in the treatment of SARS: A new trick for an old drug? CMAJ 2003;168:1289-92.
2. Cameron CE, Castro C. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis 2001;14:757-64.
3. Tam RC, Lau JY, Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother 2001;12:261-72.
4. Paroni R, Del PM, Borghi C, et al. Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers. Int J Clin Pharmacol Ther Toxicol 1989;27:301-7.
5. Hall CB, McBride JT, Walsh EE, et al. Aerolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983;308:1443-7.
6. Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325:24-9.
7. Moler FW, Steinhart CM, Ohmit SE, et al. Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group. J Pediatr 1996;128:422-8.
8. Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract (Cochrane review). In: The Cochrane Library, Issue 3, 2000. Oxford: Update Software.
9. Kimpen JL. Management of respiratory syncytial virus infection. Curr Opin Infect Dis 2001;14:323-8.
10. Mc Cormick JB, King IJ, Webb PA, et al. Lassa fever: Effective therapy with ribavirin. N Engl J Med 1986;314:20-6.
11. Di Bidceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C: A randomized, double blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
12. Bodenheimer HJ, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997;26:473-7.
13. McHutchison JG. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
14. Reichert T. Randomised, double blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-7.
15. Poynard T. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
16. Ferm VH, Willhite C, Kilhan L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 1978;17:93-101.
17. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160:3487-93.
18. Health Canada. Clinical information - Management of severe acute respiratory syndrome (SARS) in adults: Interim guidance for health care providers. (http://www.sars.gc.ca)
19. JW Huggins. U.S. Army Medical Research Institute of Infectious Diseases, personal communication. In: Severe Acute Respiratory Syndrome (SARS) and coronavirus testing - United States, 2003. MMWR 2003;52:297-302, JAMA 2003;289:2203-6.
20. Peiris JSM, Lai ST, Poon LLM, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319-25.
21. Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767-72.
22. So LK-Y, Lau ACW, Yam LCW, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003;361:1615-7.
23. Tsang KW, Ho PL, Ooi GC, et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1977-85.
24. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-93.
25. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348:1995-2005.
26. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical Features and short term outcome of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:1-9.
27. Garrison MM, Christakis DA, Harvey E, et al. Systemic corticosteroids in infant bronchiolitis: a meta-analysis. Pediatrics 2000;105;e44.
28. Bülow SM, Nir M, Levin E. Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants. Pediatrics 1999;104:e77.
29. Goebel J, Estrade B, Quinonez J, et al. Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis. Clin Pediatr (Phil) 2000;39:213-20.
30. Cade A, Brownlee KG, Conway SP, et al. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch Dis Child 2000;82:126-30.
31. Nicolaou S, Al Nakshabandi NA, Müller NL. Images in clinical medicine: Radiologic manifestations of acute respiratory syndrome. N Engl J Med 2003;348:2006.
32. Lee N, Sung J. The use of corticosteroids in SARS. New Engl J Med 2003:348:2034-5, author's reply 2034-5.
33. Oba Y. The use of corticosteroids in SARS. New Engl J Med 2003:348:2034-5.
34. Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995;107:1062-73.
35. Meduri GU, Tolley EA, Chinn A, et al. Procollagen type I and III aminoterminal propeptide levels during acute respiratory distress syndrome to methylprednisolone treatment. Am J Resp Crit Care Med 1998;158:1432-41.
36. Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in resolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998;280:159-65.
37. Wenzel RP, Edmond MB. Managing SARS amidst uncertainty. N Engl J Med 2003;348:1947-8.